MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Niitsu, N.
Right arrow Articles by Honma, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Niitsu, N.
Right arrow Articles by Honma, Y.

Vol. 58, Issue 1, 27-36, July 2000

Anticancer Derivative of Butyric Acid (Pivalyloxymethyl Butyrate) Specifically Potentiates the Cytotoxicity of Doxorubicin and Daunorubicin through the Suppression of Microsomal Glycosidic Activity

Nozomi Niitsu, Takashi Kasukabe, Akihiro Yokoyama, Junko Okabe-Kado, Yuri Yamamoto-Yamaguchi, Masanori Umeda, and Yoshio Honma

Saitama Cancer Center Research Institute, Saitama, Japan (N.N., T.K., A.Y., J.O.-K., Y.Y.-Y., Y.H.) and The 1st Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan (N.N., M.U.)

Pivalyloxymethyl butyrate (AN9) is an anticancer derivative of butyric acid. In this study, doxorubicin (DXR) and AN9 synergistically inhibited the growth of lymphoma and lung carcinoma cells, whereas there was no synergy between AN9 and antimetabolites. AN9 did not affect the intracellular uptake of DXR. Among anthracyclines and their derivatives, the synergistic effect was prominent in compounds with a daunosamine moiety, suggesting that AN9 may affect the catabolism of these compounds. The degradation of DXR in the extract from AN9-treated cells was much less than that in extract from untreated cells. AN9 did not directly inhibit the enzyme activity but rather suppressed expression of the enzyme. With respect to the expression of drug resistance-related genes, there was no significant difference between untreated and AN9-treated cells. However, AN9 significantly down-regulated the levels NADPH-cytochrome P450 reductase and DT-diaphorase mRNA in the presence of DXR but not the level of xanthine oxidase mRNA. The enhancement of the sensitivity to anthracyclines was closely associated with the suppression of the mRNA expression.

Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
C. Fang, J. Gu, F. Xie, M. Behr, W. Yang, E. D. Abel, and X. Ding
Deletion of the NADPH-Cytochrome P450 Reductase Gene in Cardiomyocytes Does Not Protect Mice against Doxorubicin-Mediated Acute Cardiac Toxicity
Drug Metab. Dispos., August 1, 2008; 36(8): 1722 - 1728.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. M. Cutts, L. P. Swift, V. Pillay, R. A. Forrest, A. Nudelman, A. Rephaeli, and D. R. Phillips
Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate
Mol. Cancer Ther., April 1, 2007; 6(4): 1450 - 1459.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
M. G Catalano, N. Fortunati, M. Pugliese, R. Poli, O. Bosco, R. Mastrocola, M. Aragno, and G. Boccuzzi
Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells.
J. Endocrinol., November 1, 2006; 191(2): 465 - 472.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. C. Marchion, E. Bicaku, J. G. Turner, A. I. Daud, D. M. Sullivan, and P. N. Munster
Synergistic Interaction between Histone Deacetylase and Topoisomerase II Inhibitors Is Mediated through Topoisomerase II{beta}
Clin. Cancer Res., December 1, 2005; 11(23): 8467 - 8475.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. S. Riddick, C. Lee, S. Ramji, E. C. Chinje, R. L. Cowen, K. J. Williams, A. V. Patterson, I. J. Stratford, C. S. Morrow, A. J. Townsend, et al.
CANCER CHEMOTHERAPY AND DRUG METABOLISM
Drug Metab. Dispos., August 1, 2005; 33(8): 1083 - 1096.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Ramji, C. Lee, T. Inaba, A. V. Patterson, and D. S. Riddick
Human NADPH-Cytochrome P450 Reductase Overexpression Does Not Enhance the Aerobic Cytotoxicity of Doxorubicin in Human Breast Cancer Cell Lines
Cancer Res., October 15, 2003; 63(20): 6914 - 6919.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Batova, L.-e. Shao, M. B. Diccianni, A. L.Y. T. Tanaka, A. Rephaeli, A. Nudelman, and J. Yu
The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines
Blood, October 16, 2002; 100(9): 3319 - 3324.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. P. Swift, S. M. Cutts, A. Rephaeli, A. Nudelman, and D. R. Phillips
Activation of Adriamycin by the pH-dependent Formaldehyde-releasing Prodrug Hexamethylenetetramine
Mol. Cancer Ther., February 1, 2002; 2(2): 189 - 198.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
E. U. Kurz, S. E. Wilson, K. B. Leader, B. P. Sampey, W. P. Allan, J. C. Yalowich, and D. J. Kroll
The Histone Deacetylase Inhibitor Sodium Butyrate Induces DNA Topoisomerase II{alpha} Expression and Confers Hypersensitivity to Etoposide in Human Leukemic Cell Lines
Mol. Cancer Ther., December 1, 2001; 1(2): 121 - 131.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. M. Cutts, A. Rephaeli, A. Nudelman, I. Hmelnitsky, and D. R. Phillips
Molecular Basis for the Synergistic Interaction of Adriamycin with the Formaldehyde-releasing Prodrug Pivaloyloxymethyl Butyrate (AN-9)
Cancer Res., November 1, 2001; 61(22): 8194 - 8202.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics